Impact of islet transplantation on glycemic control as evidenced by a continuous glucose monitoring system

Lisa Gorn, Raquel N. Faradji, Shari Messinger, Kathy Monroy, David Baidal, Tatiana Froud, John Mastrototaro, Camillo Ricordi, Rodolfo Alejandro

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: This study evaluated the effects of islet allotransplantation (ITx) on metabolic control utilizing a continuous glucose monitoring system (CGMS) and assessed its effectiveness as an indicator and predictor of graft dysfunction (GD). Methods: Glycemic control was assessed in 25 patients with type 1 diabetes mellitus (T1DM); 12 ITx recipients and 13 controls. Mean interstitial glucose, standard deviation (SD), glucose variability, and percentage of time in hyperglycemia (%GT >140 mg/dl), hypoglycemia (%GT <54 mg/dl), and normoglycemia (%GT 54-140 mg/dl) were measured in 72-hour time periods from CGMS recordings in the control group at baseline and in the ITx group at 3, 6, 9, 12, 15, and 18 months after ITx completion and were analyzed as predictors and indicators of GD. Hemoglobin A1c (HbA1c), 90-minute glucose after a mixed meal tolerance test, fasting C-peptide/glucose ratio, and insulin requirements were followed. Results: Compared to the control group, the percentage of time in hypoglycemia was significantly lower in the ITx group at all time points; time in normoglycemia was increased at all times except at 15 months; and time in hyperglycemia was significantly lower at 6, 9, 12, and 18 months. Mean glucose and glucose variability were significantly lower in the ITx group at all times except at 3 and 15 months, whereas HbA1c and 90-minute glucose were significantly lower in the ITx group at all time points. Mean glucose, SD, glucose variability, and %GT >140 mg/dl were significant as indicators but not as predictors of GD.

Original languageEnglish
Pages (from-to)221-228
Number of pages8
JournalJournal of diabetes science and technology
Volume2
Issue number2
StatePublished - Mar 1 2008

Fingerprint

Islets of Langerhans Transplantation
Glucose
Grafts
Monitoring
Transplants
Medical problems
Type 1 Diabetes Mellitus
Hypoglycemia
Hyperglycemia

Keywords

  • Continuous glucose monitoring system
  • Diabetes
  • Graft dysfunction
  • Islet transplantation
  • Islets
  • Metabolism

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Bioengineering
  • Biomedical Engineering

Cite this

Impact of islet transplantation on glycemic control as evidenced by a continuous glucose monitoring system. / Gorn, Lisa; Faradji, Raquel N.; Messinger, Shari; Monroy, Kathy; Baidal, David; Froud, Tatiana; Mastrototaro, John; Ricordi, Camillo; Alejandro, Rodolfo.

In: Journal of diabetes science and technology, Vol. 2, No. 2, 01.03.2008, p. 221-228.

Research output: Contribution to journalArticle

@article{bbc4dbfaa5cc444d95a8095bd7b8a065,
title = "Impact of islet transplantation on glycemic control as evidenced by a continuous glucose monitoring system",
abstract = "Background: This study evaluated the effects of islet allotransplantation (ITx) on metabolic control utilizing a continuous glucose monitoring system (CGMS) and assessed its effectiveness as an indicator and predictor of graft dysfunction (GD). Methods: Glycemic control was assessed in 25 patients with type 1 diabetes mellitus (T1DM); 12 ITx recipients and 13 controls. Mean interstitial glucose, standard deviation (SD), glucose variability, and percentage of time in hyperglycemia ({\%}GT >140 mg/dl), hypoglycemia ({\%}GT <54 mg/dl), and normoglycemia ({\%}GT 54-140 mg/dl) were measured in 72-hour time periods from CGMS recordings in the control group at baseline and in the ITx group at 3, 6, 9, 12, 15, and 18 months after ITx completion and were analyzed as predictors and indicators of GD. Hemoglobin A1c (HbA1c), 90-minute glucose after a mixed meal tolerance test, fasting C-peptide/glucose ratio, and insulin requirements were followed. Results: Compared to the control group, the percentage of time in hypoglycemia was significantly lower in the ITx group at all time points; time in normoglycemia was increased at all times except at 15 months; and time in hyperglycemia was significantly lower at 6, 9, 12, and 18 months. Mean glucose and glucose variability were significantly lower in the ITx group at all times except at 3 and 15 months, whereas HbA1c and 90-minute glucose were significantly lower in the ITx group at all time points. Mean glucose, SD, glucose variability, and {\%}GT >140 mg/dl were significant as indicators but not as predictors of GD.",
keywords = "Continuous glucose monitoring system, Diabetes, Graft dysfunction, Islet transplantation, Islets, Metabolism",
author = "Lisa Gorn and Faradji, {Raquel N.} and Shari Messinger and Kathy Monroy and David Baidal and Tatiana Froud and John Mastrototaro and Camillo Ricordi and Rodolfo Alejandro",
year = "2008",
month = "3",
day = "1",
language = "English",
volume = "2",
pages = "221--228",
journal = "Journal of diabetes science and technology",
issn = "1932-2968",
publisher = "Diabetes Technology Society",
number = "2",

}

TY - JOUR

T1 - Impact of islet transplantation on glycemic control as evidenced by a continuous glucose monitoring system

AU - Gorn, Lisa

AU - Faradji, Raquel N.

AU - Messinger, Shari

AU - Monroy, Kathy

AU - Baidal, David

AU - Froud, Tatiana

AU - Mastrototaro, John

AU - Ricordi, Camillo

AU - Alejandro, Rodolfo

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Background: This study evaluated the effects of islet allotransplantation (ITx) on metabolic control utilizing a continuous glucose monitoring system (CGMS) and assessed its effectiveness as an indicator and predictor of graft dysfunction (GD). Methods: Glycemic control was assessed in 25 patients with type 1 diabetes mellitus (T1DM); 12 ITx recipients and 13 controls. Mean interstitial glucose, standard deviation (SD), glucose variability, and percentage of time in hyperglycemia (%GT >140 mg/dl), hypoglycemia (%GT <54 mg/dl), and normoglycemia (%GT 54-140 mg/dl) were measured in 72-hour time periods from CGMS recordings in the control group at baseline and in the ITx group at 3, 6, 9, 12, 15, and 18 months after ITx completion and were analyzed as predictors and indicators of GD. Hemoglobin A1c (HbA1c), 90-minute glucose after a mixed meal tolerance test, fasting C-peptide/glucose ratio, and insulin requirements were followed. Results: Compared to the control group, the percentage of time in hypoglycemia was significantly lower in the ITx group at all time points; time in normoglycemia was increased at all times except at 15 months; and time in hyperglycemia was significantly lower at 6, 9, 12, and 18 months. Mean glucose and glucose variability were significantly lower in the ITx group at all times except at 3 and 15 months, whereas HbA1c and 90-minute glucose were significantly lower in the ITx group at all time points. Mean glucose, SD, glucose variability, and %GT >140 mg/dl were significant as indicators but not as predictors of GD.

AB - Background: This study evaluated the effects of islet allotransplantation (ITx) on metabolic control utilizing a continuous glucose monitoring system (CGMS) and assessed its effectiveness as an indicator and predictor of graft dysfunction (GD). Methods: Glycemic control was assessed in 25 patients with type 1 diabetes mellitus (T1DM); 12 ITx recipients and 13 controls. Mean interstitial glucose, standard deviation (SD), glucose variability, and percentage of time in hyperglycemia (%GT >140 mg/dl), hypoglycemia (%GT <54 mg/dl), and normoglycemia (%GT 54-140 mg/dl) were measured in 72-hour time periods from CGMS recordings in the control group at baseline and in the ITx group at 3, 6, 9, 12, 15, and 18 months after ITx completion and were analyzed as predictors and indicators of GD. Hemoglobin A1c (HbA1c), 90-minute glucose after a mixed meal tolerance test, fasting C-peptide/glucose ratio, and insulin requirements were followed. Results: Compared to the control group, the percentage of time in hypoglycemia was significantly lower in the ITx group at all time points; time in normoglycemia was increased at all times except at 15 months; and time in hyperglycemia was significantly lower at 6, 9, 12, and 18 months. Mean glucose and glucose variability were significantly lower in the ITx group at all times except at 3 and 15 months, whereas HbA1c and 90-minute glucose were significantly lower in the ITx group at all time points. Mean glucose, SD, glucose variability, and %GT >140 mg/dl were significant as indicators but not as predictors of GD.

KW - Continuous glucose monitoring system

KW - Diabetes

KW - Graft dysfunction

KW - Islet transplantation

KW - Islets

KW - Metabolism

UR - http://www.scopus.com/inward/record.url?scp=67651239780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651239780&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:67651239780

VL - 2

SP - 221

EP - 228

JO - Journal of diabetes science and technology

JF - Journal of diabetes science and technology

SN - 1932-2968

IS - 2

ER -